{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:30:12Z","timestamp":1790951412076,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI147109"],"award-info":[{"award-number":["1R01AI147109"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32 AI125207"],"award-info":[{"award-number":["T32 AI125207"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is a crucial need for an improved H3N2 influenza virus vaccine due to low vaccine efficacy rates and increased morbidity and mortality associated with H3N2-dominated influenza seasons. Here, we utilize a computational design strategy to produce epitope-optimized, broadly cross-reactive H3 hemagglutinins in order to create a universal H3N2 influenza vaccine. The Epigraph immunogens are designed to maximize the viral population frequency of epitopes incorporated into the immunogen. We compared our Epigraph H3 vaccine to the traditional egg-based inactivated influenza vaccine from 2018\u201319, FluZone. Epigraph vaccination-induced stronger cross-reactive antibody responses than FluZone against 18 H3N2 viruses isolated from 1968 to 2019 in both mice and ferrets, with protective hemagglutination inhibition titers against 93\u2013100% of the contemporary H3N2 strains compared to only 27% protection measured from FluZone. In addition, Epigraph vaccination-induced strong cross-reactive T-cell immunity which significantly contributes to protection against lethal influenza virus infection. Finally, Epigraph vaccination protected ferrets from influenza disease after challenge with two H3N2 viruses. The superior cross-reactive immunity induced by these Epigraph immunogens supports their development as a universal H3N2 influenza vaccine.<\/jats:p>","DOI":"10.1038\/s41541-022-00492-y","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T10:06:31Z","timestamp":1655978791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["An epitope-optimized human H3N2 influenza vaccine induces broadly protective immunity in mice and ferrets"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6702-0079","authenticated-orcid":false,"given":"Brianna L.","family":"Bullard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"DeBeauchamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Pekarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Petro-Turnquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7535-0545","authenticated-orcid":false,"given":"Peter","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4397-7132","authenticated-orcid":false,"given":"Richard J.","family":"Webby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5029-0662","authenticated-orcid":false,"given":"Eric A.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"492_CR1","first-page":"659","volume":"36","author":"LR Clayville","year":"2011","unstructured":"Clayville, L. R. Influenza update: a review of currently available vaccines. P T 36, 659\u2013684 (2011).","journal-title":"P T"},{"key":"492_CR2","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3201\/eid2407.171270","volume":"24","author":"J Bresee","year":"2018","unstructured":"Bresee, J. et al. Progress and remaining gaps in estimating the global disease burden of influenza. Emerg. Infect. Dis. 24, 1173 (2018).","journal-title":"Emerg. Infect. Dis."},{"key":"492_CR3","unstructured":"WHO. Influenza (Seasonal), https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal) (2018)."},{"key":"492_CR4","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","volume":"391","author":"AD Iuliano","year":"2018","unstructured":"Iuliano, A. D. et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet (Lond., Engl.) 391, 1285\u20131300 (2018).","journal-title":"Lancet (Lond., Engl.)"},{"key":"492_CR5","doi-asserted-by":"publisher","first-page":"e1001977","DOI":"10.1371\/journal.pmed.1001977","volume":"13","author":"KE Lafond","year":"2016","unstructured":"Lafond, K. E. et al. Global role and burden of influenza in pediatric respiratory hospitalizations, 1982\u20132012: a systematic analysis. PLoS Med. 13, e1001977 (2016).","journal-title":"PLoS Med."},{"key":"492_CR6","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/irv.12074","volume":"7","author":"MD Van Kerkhove","year":"2013","unstructured":"Van Kerkhove, M. D., Hirve, S., Koukounari, A. & Mounts, A. W. Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries. Influenza Other Respir. Viruses 7, 872\u2013886 (2013).","journal-title":"Influenza Other Respir. Viruses"},{"key":"492_CR7","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1080\/21645515.2018.1462639","volume":"14","author":"JD Allen","year":"2018","unstructured":"Allen, J. D. & Ross, T. M. H3N2 influenza viruses in humans: viral mechanisms, evolution, and evaluation. Hum. Vaccines immunother. 14, 1840\u20131847 (2018).","journal-title":"Hum. Vaccines immunother."},{"key":"492_CR8","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2105\/AJPH.2019.305557","volume":"110","author":"BJ Jester","year":"2020","unstructured":"Jester, B. J., Uyeki, T. M. & Jernigan, D. B. Fifty years of influenza A(H3N2) following the pandemic of 1968. Am. J. Public Health 110, 669\u2013676 (2020).","journal-title":"Am. J. Public Health"},{"key":"492_CR9","unstructured":"CDC. CDC Seasonal Flu Vaccine Effectiveness Studies, https:\/\/www.cdc.gov\/flu\/vaccines-work\/effectiveness-studies.htm (2021)."},{"key":"492_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/vaccines6020028","volume":"6","author":"JA Lewnard","year":"2018","unstructured":"Lewnard, J. A. & Cobey, S. Immune history and influenza vaccine effectiveness. Vaccines 6, 28 (2018).","journal-title":"Vaccines"},{"key":"492_CR11","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S1473-3099(16)00129-8","volume":"16","author":"EA Belongia","year":"2016","unstructured":"Belongia, E. A. et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect. Dis. 16, 942\u2013951 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"492_CR12","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.2105\/AJPH.87.12.1944","volume":"87","author":"L Simonsen","year":"1997","unstructured":"Simonsen, L. et al. The impact of influenza epidemics on mortality: introducing a severity index. Am. J. Public Health 87, 1944\u20131950 (1997).","journal-title":"Am. J. Public Health"},{"key":"492_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jama.289.2.179","volume":"289","author":"WW Thompson","year":"2003","unstructured":"Thompson, W. W. et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289, 179\u2013186 (2003).","journal-title":"JAMA"},{"key":"492_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/sim.7203","volume":"37","author":"J Theiler","year":"2018","unstructured":"Theiler, J. & Korber, B. Graph-based optimization of epitope coverage for vaccine antigen design. Stat. Med. 37, 181\u2013194 (2018).","journal-title":"Stat. Med."},{"key":"492_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/srep33987","volume":"6","author":"J Theiler","year":"2016","unstructured":"Theiler, J. et al. Epigraph: a vaccine design tool applied to an HIV therapeutic vaccine and a pan-filovirus vaccine. Sci. Rep. 6, 33987 (2016).","journal-title":"Sci. Rep."},{"key":"492_CR16","doi-asserted-by":"publisher","first-page":"e1007564","DOI":"10.1371\/journal.ppat.1007564","volume":"15","author":"MN Rahim","year":"2019","unstructured":"Rahim, M. N. et al. Complete protection of the BALB\/c and C57BL\/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine. PLoS Pathog. 15, e1007564 (2019).","journal-title":"PLoS Pathog."},{"key":"492_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21508-6","volume":"12","author":"BL Bullard","year":"2021","unstructured":"Bullard, B. L. et al. Epigraph hemagglutinin vaccine induces broad cross-reactive immunity against swine H3 influenza virus. Nat. Commun. 12, 1203 (2021).","journal-title":"Nat. Commun."},{"key":"492_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-10-18","volume":"10","author":"L Coudeville","year":"2010","unstructured":"Coudeville, L. et al. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med. Res. Methodol. 10, 18 (2010).","journal-title":"BMC Med. Res. Methodol."},{"key":"492_CR19","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1097\/INF.0b013e3182367662","volume":"30","author":"S Black","year":"2011","unstructured":"Black, S. et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr. Infect. Dis. J. 30, 1081\u20131085 (2011).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"492_CR20","first-page":"767","volume":"70","author":"D Hobson","year":"1972","unstructured":"Hobson, D., Curry, R. L., Beare, A. S. & Ward-Gardner, A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.) 70, 767\u2013777 (1972).","journal-title":"J. Hyg. (Lond.)"},{"key":"492_CR21","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1084\/jem.186.12.2063","volume":"186","author":"MB Graham","year":"1997","unstructured":"Graham, M. B. & Braciale, T. J. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J. Exp. Med. 186, 2063\u20132068 (1997).","journal-title":"J. Exp. Med."},{"key":"492_CR22","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1099\/0022-1317-82-11-2697","volume":"82","author":"PP Heinen","year":"2001","unstructured":"Heinen, P. P., de Boer-Luijtze, E. A. & Bianchi, A. T. J. Respiratory and systemic humoral and cellular immune responses of pigs to a heterosubtypic influenza A virus infection. J. Gen. Virol. 82, 2697\u20132707 (2001).","journal-title":"J. Gen. Virol."},{"key":"492_CR23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1242\/dmm.007823","volume":"4","author":"JA Belser","year":"2011","unstructured":"Belser, J. A., Katz, J. M. & Tumpey, T. M. The ferret as a model organism to study influenza A virus infection. Dis. Model Mech. 4, 575\u2013579 (2011).","journal-title":"Dis. Model Mech."},{"key":"492_CR24","doi-asserted-by":"publisher","first-page":"ofv067","DOI":"10.1093\/ofid\/ofv067","volume":"2","author":"A Benoit","year":"2015","unstructured":"Benoit, A. et al. Hemagglutination inhibition antibody titers as a correlate of protection against seasonal A\/H3N2 influenza disease. Open Forum Infect. Dis. 2, ofv067\u2013ofv067 (2015).","journal-title":"Open Forum Infect. Dis."},{"key":"492_CR25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.4161\/hv.6.10.12636","volume":"6","author":"L Coudeville","year":"2010","unstructured":"Coudeville, L., Andre, P., Bailleux, F., Weber, F. & Plotkin, S. A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes. Hum. vaccines 6, 841\u2013848 (2010).","journal-title":"Hum. vaccines"},{"key":"492_CR26","first-page":"63","volume":"115","author":"JC de Jong","year":"2003","unstructured":"de Jong, J. C. et al. Haemagglutination-inhibiting antibody to influenza virus. Dev. Biol. 115, 63\u201373 (2003).","journal-title":"Dev. Biol."},{"key":"492_CR27","doi-asserted-by":"publisher","first-page":"e2975","DOI":"10.1371\/journal.pone.0002975","volume":"3","author":"S Sasaki","year":"2008","unstructured":"Sasaki, S. et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS ONE 3, e2975 (2008).","journal-title":"PLoS ONE"},{"key":"492_CR28","doi-asserted-by":"crossref","unstructured":"Spitaels, J., Roose, K. & Saelens, X. Influenza and memory T cells: how to awake the force. Vaccines (Basel) 4, 33 (2016).","DOI":"10.3390\/vaccines4040033"},{"key":"492_CR29","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1164\/rccm.201411-1988OC","volume":"191","author":"AC Hayward","year":"2015","unstructured":"Hayward, A. C. et al. Natural T cell-mediated protection against seasonal and pandemic influenza. Results of the flu watch cohort study. Am. J. Respir. Crit. Care Med. 191, 1422\u20131431 (2015).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"492_CR30","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/nm.3350","volume":"19","author":"S Sridhar","year":"2013","unstructured":"Sridhar, S. et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19, 1305\u20131312 (2013).","journal-title":"Nat. Med."},{"key":"492_CR31","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.3389\/fimmu.2019.01400","volume":"10","author":"M Auladell","year":"2019","unstructured":"Auladell, M. et al. Recalling the future: immunological memory toward unpredictable influenza viruses. Front. Immunol. 10, 1400 (2019).","journal-title":"Front. Immunol."},{"key":"492_CR32","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1086\/605893","volume":"200","author":"MJ Memoli","year":"2009","unstructured":"Memoli, M. J. et al. Recent human influenza A\/H3N2 virus evolution driven by novel selection factors in addition to antigenic drift. J. Infect. Dis. 200, 1232\u20131241 (2009).","journal-title":"J. Infect. Dis."},{"key":"492_CR33","doi-asserted-by":"publisher","unstructured":"Groves, H. T. et al. Mouse models of influenza infection with circulating strains to test seasonal vaccine efficacy. Front. Immunol. 9, https:\/\/doi.org\/10.3389\/fimmu.2018.00126 (2018).","DOI":"10.3389\/fimmu.2018.00126"},{"key":"492_CR34","doi-asserted-by":"publisher","first-page":"21474","DOI":"10.1073\/pnas.1218841110","volume":"109","author":"YP Lin","year":"2012","unstructured":"Lin, Y. P. et al. Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc. Natl. Acad. Sci. 109, 21474\u201321479 (2012).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"492_CR35","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nrmicro3362","volume":"12","author":"Y Shi","year":"2014","unstructured":"Shi, Y., Wu, Y., Zhang, W., Qi, J. & Gao, G. F. Enabling the \u2018host jump\u2019: structural determinants of receptor-binding specificity in influenza A viruses. Nat. Rev. Microbiol. 12, 822\u2013831 (2014).","journal-title":"Nat. Rev. Microbiol."},{"key":"492_CR36","doi-asserted-by":"publisher","first-page":"12578","DOI":"10.1073\/pnas.1712377114","volume":"114","author":"SJ Zost","year":"2017","unstructured":"Zost, S. J. et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc. Natl Acad. Sci. USA 114, 12578\u201312583 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"492_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.chom.2016.11.004","volume":"21","author":"W Peng","year":"2017","unstructured":"Peng, W. et al. Recent H3N2 viruses have evolved specificity for extended, branched human-type receptors, conferring potential for increased avidity. Cell Host Microbe 21, 23\u201334 (2017).","journal-title":"Cell Host Microbe"},{"key":"492_CR38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/sysbio\/syq010","volume":"59","author":"S Guindon","year":"2010","unstructured":"Guindon, S. et al. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst. Biol. 59, 307\u2013321 (2010).","journal-title":"Syst. Biol."},{"key":"492_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14891-y","volume":"7","author":"A Lingel","year":"2017","unstructured":"Lingel, A., Bullard, B. L. & Weaver, E. A. Efficacy of an adenoviral vectored multivalent centralized influenza vaccine. Sci. Rep. 7, 14912 (2017).","journal-title":"Sci. Rep."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00492-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00492-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00492-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T18:43:30Z","timestamp":1669315410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00492-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["492"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00492-y","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]},"assertion":[{"value":"17 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Eric A. Weaver is an inventor of the Epigraph immunogens used in this study and has a patent application in progress (Application: 62\/734,791, International Application: PCT\/US19\/52137). Authors Brianna L. Bullard, Jennifer DeBeauchamp, Matthew J. Pekarek, Erika Petro-Turnquist, Peter Vogel, and Richard J. Webby declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}